Scarica l'app Stockscreener
2.21
5.24%
0.11
Dopo l'orario di chiusura:
2.21
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Wall Street Zen Upgrades Akebia Therapeutics (NASDAQ:AKBA) to "Strong-Buy" - MarketBeat
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockJobs Report & Weekly Momentum Stock Picks - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsJuly 2025 Recap & Growth Focused Stock Reports - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsWeekly Trend Recap & Daily Profit Maximizing Trade Tips - newser.com
HC Wainwright Issues Pessimistic Forecast for AKBA Earnings - MarketBeat
How high can Akebia Therapeutics Inc. stock go2025 Sector Review & Safe Investment Capital Preservation Plans - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth funds2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growthJuly 2025 Macro Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat
Is this a good reentry point in Akebia Therapeutics Inc.2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
How Akebia Therapeutics Inc. stock reacts to job market data2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockJuly 2025 Action & Fast Momentum Stock Entry Tips - newser.com
Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure - Markets Mojo
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat
How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener
HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock2025 Big Picture & Fast Gain Swing Alerts - newser.com
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks
Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks
Will Akebia Therapeutics Inc. stock benefit from sector rotationJuly 2025 Breakouts & High Yield Equity Trading Tips - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boomTrade Risk Report & AI Based Buy and Sell Signals - newser.com
Health Care Down on Mixed EarningsHealth Care Roundup - MarketScreener
BTIG Lowers Akebia Therapeutics (AKBA) Price Target by 50% | AKB - GuruFocus
Why Is Akebia Therapeutics Stock Plunging TodayAkebia Therapeutics (NASDAQ:AKBA) - Benzinga
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA) - Seeking Alpha
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications - TipRanks
Akebia stock plunges as kidney drug expansion plans scrapped - The Business Journals
Akebia scraps plan for Vafseo trial after discussions with FDA - Fierce Pharma
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion - Stocktwits
Akebia stock tumbles after FDA meeting on vadadustat trial design By Investing.com - Investing.com Canada
Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs - Citeline News & Insights
Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Morning Market Movers: CMBM, LRN, VRNS, AKBA See Big Swings - RTTNews
FDA setback prompts Akebia to give up on broader Vafseo label - The Pharma Letter
Akebia Therapeutics Stock Up 14%, Buy Or Wait? - Trefis
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
3.18%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):